{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:18:33Z","timestamp":1773411513590,"version":"3.50.1"},"reference-count":62,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2016,3,3]]},"DOI":"10.1185\/03007995.2015.1123145","type":"journal-article","created":{"date-parts":[[2015,12,29]],"date-time":"2015-12-29T15:23:13Z","timestamp":1451402593000},"page":"441-452","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":12,"title":["A review of aripiprazole long-acting injection"],"prefix":"10.1185","volume":"32","author":[{"given":"Pierre","family":"Chue","sequence":"first","affiliation":[{"name":"University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Chue","sequence":"additional","affiliation":[{"name":"Clinical Trials and Research Program, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,12,29]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0016-5"},{"key":"e_1_3_3_3_1","first-page":"115","article-title":"Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature","volume":"49","author":"Graffino M","year":"2014","unstructured":"Graffino M, Montemagni C, Mingrone C, Rocca P. Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature. Riv Psichiatr 2014;49:115-23","journal-title":"Riv Psichiatr"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0107"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.55.8.886"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.837"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.9101tx2c"},{"key":"e_1_3_3_8_1","volume-title":"Antipsychotic Long-Acting Injections","author":"Chue P","year":"2010","unstructured":"Chue P. Risperidone long-acting injection. In: Haddad P, Lambert T, Lauriello J (eds). Antipsychotic Long-Acting Injections. Oxford: Oxford University Press, 2010 Chapter 5. 93-130"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.553193"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.686169"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/157488712799363307"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/11208640-000000000-00000"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.12.137"},{"key":"e_1_3_3_14_1","first-page":"CD008296","article-title":"Paliperidone palmitate for schizophrenia","volume":"6","author":"Nussbaum AM","year":"2012","unstructured":"Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Sys Rev 2012;6:CD008296","journal-title":"Cochrane Database Sys Rev"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S20657"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S32972"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.GOAG.043013"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S52486"},{"key":"e_1_3_3_19_1","unstructured":"Lincoln J. Long-acting injectable aripiprazole for adult schizophrenia. Curr Psychiatry 2013;12"},{"key":"e_1_3_3_20_1","unstructured":"Long-acting injectable aripiprazole (Abilify Maintena) for schizophrenia. Med Lett Drugs Ther 2013;55:34-6"},{"key":"e_1_3_3_21_1","doi-asserted-by":"crossref","unstructured":"Rauch AS Fleischhacker WW. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs. 2013;27:637-652.","DOI":"10.1007\/s40263-013-0083-9"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2014.09.002"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0231-7"},{"key":"e_1_3_3_24_1","unstructured":"National Institute for Health and Care Excellence. Schizophrenia: aripiprazole prolonged-release suspension for injection. NICE Advice (ESNM39). 2014. Available at: http:\/\/www.nice.org.uk\/advice\/esnm39#key\u2013points 10 March 2015"},{"key":"e_1_3_3_25_1","first-page":"1","article-title":"The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia","volume":"2","author":"Kahn RS","year":"2015","unstructured":"Kahn RS, Giannopoulou A. The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. Exp Rev Neurother 2015;2:1-13","journal-title":"Exp Rev Neurother"},{"key":"e_1_3_3_26_1","unstructured":"Saklad S. Texas State Department of Health Formulary Monograph Aripiprazole for Extended-Release Injectable Suspension (Aripiprazole Long-acting Antipsychotic Injection [LAI]; Abilify Maintena). 2013. Available at: http:\/\/www.dshs.state.tx.us\/"},{"key":"e_1_3_3_27_1","unstructured":"Lundbeck Canada Inc. Abilify Maintena. Product Monograph. 2014 10 March 2015"},{"key":"e_1_3_3_28_1","unstructured":"Otsuka America Pharmaceutical Inc. Abilify Maintena. Product Monograph. 2013. Revised 6 February 2014"},{"key":"e_1_3_3_29_1","unstructured":"Bristol-Myers Squibb. Abilify. Product Monograph. 2009. Revised 27 May 2013"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1006356"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2015.02.001"},{"key":"e_1_3_3_32_1","unstructured":"European Medicines Agency. Abilify Maintena European Public Assessment Report. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_\u2013_Product_Information\/human\/002755\/WC500156111.pdf 23 January 2015"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.821973"},{"key":"e_1_3_3_34_1","unstructured":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and BC Mental Health & Addiction Services (BCMHAS). Switching antipsychotic medications. Available at: http:\/\/switchrx.ca 10 March 2015"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09168"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.06.041"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07530"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.134213"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.09.019"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.3371\/CSRP.KASA.022015"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2014.12.013"},{"key":"e_1_3_3_42_1","doi-asserted-by":"crossref","unstructured":"Naber D Hansen K Forray C et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res 2015: 168(1-2):498-504","DOI":"10.1016\/j.schres.2015.07.007"},{"key":"e_1_3_3_43_1","first-page":"171","article-title":"Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia","volume":"28","author":"Fleischhacker WW","year":"2013","unstructured":"Fleischhacker WW, Sanchez R, Johnson B, et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol 2013;28:171-6","journal-title":"Int Clin Psychopharmacol"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S80479"},{"key":"e_1_3_3_45_1","unstructured":"Thedford S. Aripiprazole Intramuscular Depot (Abilify Maintena\u2122) Formulary Review Statewide Pharmacy and Therapeutics Committee October 18 2013. Available at: http:\/\/www.pharmacy.umaryland.edu\/programs\/mhaformulary\/formulary%20reviews\/pdfs\/2013\/Aripiprazole%20ER%20injection.pdf"},{"key":"e_1_3_3_46_1","unstructured":"Pan Mersey Area Prescribing Committee Prescribing Policy Statement Ref: Ps39. Final APC Board Date: 24 Sep 2014 Accessed 8 August 2015 https:\/\/protect-us.mimecast.com\/s\/Jq6kBKiAM0Z4fn http:\/\/www.panmerseyapc.nhs.uk\/recommendations\/documents\/PS39.pdf"},{"key":"e_1_3_3_47_1","unstructured":"Sussex Partnership NHS Foundation Trust. Aripiprazole Long-Acting Injection (Abilify Maintena) Guidelines for Prescribing and Administration. Version 3 \u2013 August 2014 Accessed 30 August 2015 https:\/\/protect-us.mimecast.com\/s\/X8vJBRuo7a8lT6 http:\/\/www.sussexpartnership.nhs.uk\/sites\/default\/files\/documents\/aripiprazole_lai_guidelines_-_aug_14.pdf"},{"key":"e_1_3_3_48_1","unstructured":"Scottish Medicines Consortium NHS Scotland. Aripiprazole 400mg Powder and Solvent for Prolonged Release Suspension for Injection (Abilify Maintena) SMC No. 962\/14 Accessed 30 August 2015 https:\/\/protect-us.mimecast.com\/s\/7GwOB4hw6GvYT0 https:\/\/www.scottishmedicines.org.uk\/files\/advice\/aripiprazole_Abilify_FINAL_April_2014_for_website.pdf"},{"key":"e_1_3_3_49_1","unstructured":"All Wales Medicines Strategy Group. Final Appraisal Recommendation \u2013 2214: Aripiprazole (Abilify Maintena) 400\u2009mg powder and solvent for prolonged release suspension for injection. July 2014 Accessed 10 August 2015 https:\/\/protect-us.mimecast.com\/s\/EJNGBkfm60DgfV http:\/\/www.awmsg.org\/awmsgonline\/app\/appraisalinfo\/909"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.917089"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.804411"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1586\/erp.12.23"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-013-0016-2"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e3182854f70"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32835d30ae"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/088740341305805s03"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/088740341305805s04"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(14)70001-X"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/088740341305805s05"},{"key":"e_1_3_3_60_1","unstructured":"National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults. The NICE Guideline on Treatment and Management (updated edition 2014). National Clinical Guideline Number 178. National Collaborating Centre for Mental Health Commissioned by the National Institute for Heal and Care Excellence. Available at: http:\/\/www.nice.org.uk\/guidance\/cg178\/resources\/cg178\u2013psychosis\u2013and\u2013schizophrenia\u2013in\u2013adults\u2013full\u2013guideline3 10 June 2015"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0241"},{"key":"e_1_3_3_62_1","doi-asserted-by":"crossref","unstructured":"Lin X Xu Y Tang X et al. A uniform ultra-small microsphere\/SAIB hybrid depot with low burst release for long-term continuous drug release. Pharm Res. 2015;32(II):3708-21","DOI":"10.1007\/s11095-015-1731-1"},{"key":"e_1_3_3_63_1","doi-asserted-by":"crossref","unstructured":"Meltzer HY Risinger R Nasrallah HA et al. A randomized double-blind placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J. Clin Psychiatry. 2015;76(8):1085-90","DOI":"10.4088\/JCP.14m09741"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007995.2015.1123145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T19:26:36Z","timestamp":1770924396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007995.2015.1123145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,29]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3,3]]}},"alternative-id":["10.1185\/03007995.2015.1123145"],"URL":"https:\/\/doi.org\/10.1185\/03007995.2015.1123145","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-11-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}